61
Participants
Start Date
September 9, 2015
Primary Completion Date
August 2, 2018
Study Completion Date
August 2, 2018
Part 1: LJN452
LJN452 capsules administered once daily for 28 days
Part 1: Placebo
Matching placebo capsules administered once daily for 28 days
Part 2: LJN452 Dose level 1
LJN452 capsules administered once a day for 12 weeks
Part 2: Placebo
Matching placebo to LJN452 administered once a day for 12 weeks
Part 2: LJN452 Dose level 2
LJN452
Novartis Investigative Site, Manhasset
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Marietta
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Hanover
Novartis Investigative Site, Miami
Novartis Investigative Site, Chicago
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Dallas
Novartis Investigative Site, San Antonio
Novartis Investigative Site, München
Novartis Investigative Site, Rialto
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Seattle
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Samara
Novartis Investigative Site, Calgary
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Lodz
Novartis Investigative Site, Mysłowice
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Wroclaw
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Hull
Novartis Investigative Site, London
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY